ABCG2 p.Leu554Pro

Predicted by SNAP2: A: D (80%), C: D (66%), D: D (91%), E: D (91%), F: N (53%), G: D (85%), H: D (91%), I: D (53%), K: D (91%), M: N (57%), N: D (91%), P: D (95%), Q: D (91%), R: D (91%), S: D (91%), T: D (91%), V: D (66%), W: D (91%), Y: D (80%),
Predicted by PROVEAN: A: D, C: D, D: D, E: D, F: N, G: D, H: D, I: N, K: D, M: N, N: D, P: D, Q: D, R: D, S: D, T: D, V: N, W: D, Y: D,

[switch to compact view]
Comments [show]
Publications
[hide] Kage K, Tsukahara S, Sugiyama T, Asada S, Ishikawa E, Tsuruo T, Sugimoto Y
Dominant-negative inhibition of breast cancer resistance protein as drug efflux pump through the inhibition of S-S dependent homodimerization.
Int J Cancer. 2002 Feb 10;97(5):626-30., 2002-02-10 [PMID:11807788] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Doyle LA, Ross DD
Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
Oncogene. 2003 Oct 20;22(47):7340-58., 2003-10-20 [PMID:14576842] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Xia CQ, Liu N, Yang D, Miwa G, Gan LS
Expression, localization, and functional characteristics of breast cancer resistance protein in Caco-2 cells.
Drug Metab Dispos. 2005 May;33(5):637-43. Epub 2005 Feb 16., [PMID:15716365] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Henriksen U, Gether U, Litman T
Effect of Walker A mutation (K86M) on oligomerization and surface targeting of the multidrug resistance transporter ABCG2.
J Cell Sci. 2005 Apr 1;118(Pt 7):1417-26. Epub 2005 Mar 15., 2005-04-01 [PMID:15769853] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Sugimoto Y, Tsukahara S, Ishikawa E, Mitsuhashi J
Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics.
Cancer Sci. 2005 Aug;96(8):457-65., [PMID:16108826] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Mao Q, Unadkat JD
Role of the breast cancer resistance protein (ABCG2) in drug transport.
AAPS J. 2005 May 11;7(1):E118-33., [PMID:16146333] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Polgar O, Ozvegy-Laczka C, Robey RW, Morisaki K, Okada M, Tamaki A, Koblos G, Elkind NB, Ward Y, Dean M, Sarkadi B, Bates SE
Mutational studies of G553 in TM5 of ABCG2: a residue potentially involved in dimerization.
Biochemistry. 2006 Apr 25;45(16):5251-60., 2006-04-25 [PMID:16618113] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Li YF, Polgar O, Okada M, Esser L, Bates SE, Xia D
Towards understanding the mechanism of action of the multidrug resistance-linked half-ABC transporter ABCG2: a molecular modeling study.
J Mol Graph Model. 2007 Mar;25(6):837-51. Epub 2006 Aug 30., [PMID:17027309] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Hazai E, Bikadi Z
Homology modeling of breast cancer resistance protein (ABCG2).
J Struct Biol. 2008 Apr;162(1):63-74. Epub 2007 Dec 15., [PMID:18249138] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]

[hide] Mo W, Qi J, Zhang JT
Different roles of TM5, TM6, and ECL3 in the oligomerization and function of human ABCG2.
Biochemistry. 2012 May 1;51(17):3634-41. Epub 2012 Apr 19., [PMID:22497316] [PubMed]

Abstract [show]
Comments [show]
Sentences [show]